<unk>  is indicated for treatment of adults with myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS with the following French American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia CMML) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups. MDS is a type of blood cancer in which blood cells in the bone marrow are defective leading to a low number of one or more types of blood cells.
Decitabine/cedazuridine
Trifluridine/tipiracil
Zalcitabine
Trifluridine
Bortezomib/dexamethasone
Daunorubicin/cytarabine
Apricitabine
Lenalidomide